Best Immunotherapy Companies in Paris, France
The 31 best Immunotherapy companies in Paris, France in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abivax.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Paris
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Abivax Developer of therapeutics for chronic inflammatory diseases | $320M | 44 mo ago | Public | — | 2014 | DrupalPHPAmazon Web Services+32 | 616 patents Small-molecule quinoline/phenyl derivatives for antiviral and anti-inflammatory therapies | — |
| 2 | Cellectis Developer of cancer immunotherapies based on gene-edited CAR T-cells 64Patents top 20%Funding top 25%Product top 29%Innovation top 30% All 11 signals ▾Patentstop 20% Fundingtop 25% Producttop 29% Innovationtop 30% Newstop 33% Markettop 38% Moattop 41% Globaltop 45% Growthtop 48% Talentbottom 49% Techbottom 46% Patents: 1,579 patents matched (strict assignee match) · 326 filings since 2022 vs 610 in 2017-21 Funding: Raised $267M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $267M | 30 mo ago | Public | Andre Choulika Chief Executive Officer | 1999 | ExpressionEngineApple iCloud MailMicrosoft 365+14 | 1,572 patents Genetic engineering of immune cells for CAR/TCR therapies and gene‑editing platforms | — |
| 3 | Inotrem Developer of peptide immunotherapies for treating septic shock and acute myocardial infarction | $122M | 36 mo ago | Series B | Marc Derive Co-Founder and CSO | 2013 | WordPressMySQLPHP+23 | 52 patents TREM‑1 targeted therapeutics and diagnostics for inflammation, sepsis, and cardiovascular risk | — |
| 4 | Mnemo Therapeutics Developer of cell therapy platforms for tumors and blood cancer | $91M | 64 mo ago | Series A | Alain Maiore Co-Founder & ex-CEO | 2018 | — | 58 patents Cancer immunotherapy via neoantigen peptides and SUV39H1 epigenetic modulation | — |
| 5 | TheraVectys Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection | $62M | 69 mo ago | Series D | Ye Tian CEO | 2005 | — | 176 patents Lentiviral vector platforms for viral antigen gene therapy and vaccine development | — |
| 6 | Egle Therapeutics Provider of T cells based therapeutics for oncology and autoimmune diseases 45Funding top 34%Talent top 38%Moat top 39%Patents top 40% All 7 signals ▾Fundingtop 34% Talenttop 38% Moattop 39% Patentstop 40% Innovationbottom 49% Marketbottom 44% Globalbottom 43% Funding: Raised $46.6M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $47M | 19 mo ago | Series A | Eliane Piaggio Co-Founder | 2020 | — | 11 patents Engineered cytokine and fusion protein therapeutics for cancer immunotherapy | — |
| 7 | Genticel Developer of immunotherapies to treat infectious diseases and cervical cancer using CyaA vector technology | $41M | 162 mo ago | Series C | — | 2001 | — | 50 patents CyaA-based chimeric vaccine proteins for therapeutic and prophylactic immune responses | — |
| 8 | Acticor Biotech Developing immunotherapeutics for treating ischemic stroke | $31M | 84 mo ago | Public | Gilles Avenard CEO | 2013 | Webflow EcommerceWebflowApple iCloud Mail+13 | 58 patents GPVI-targeted antibody therapeutics for antiplatelet and cardiovascular disease treatment | — |
| 9 | Advesya Developer of therapies for the treatment of cancer and autoimmune diseases | $26M | 57 mo ago | Series B | Ksenija Pavletic Chief Executive Officer | 2020 | — | 8 patents IL-1RAP-targeted antibody-drug conjugates and CAR‑T cell therapies for cancer | — |
| 10 | Neovacs CDMO focused on manufacturing of vaccines | $18M | 95 mo ago | Public | Hugo Brugiere CEO | 1993 | JoomlaPHPUIKit+11 | 168 patents IL-4/IL-13 cytokine immunotherapies and mRNA vaccine formulations for immune modulation | — |
| 11 | Ermium Therapeutics Developer of therapies for auto-immune inflammatory diseases | $13M | 52 mo ago | Series A | — | 2019 | — | 9 patents Small-molecule CXCR4 modulators based on cyclic isothiourea scaffolds | — |
| 12 | LiMM Therapeutics Providers of therapeutics based on neuronal and innate lymphoid cells | $9M | 60 mo ago | Seed | Henrique Veiga Fernandes Founder | 2019 | — | 7 patents Therapeutic modulation of ILC2 cell pathways for treating inflammatory and allergic diseases | — |
| 13 | Oncovita Developer of virus-derived vaccine technology to treat cancer | $9M | 35 mo ago | Series A | Frederic Tangy Co-Founder | 2015 | — | — | — |
| 14 | Peptinov Developer of anti-cytokine immunotherapies for the treatment of chronic inflammatory diseases | $6M | 35 mo ago | Series A | Rene Azoulai CEO | 2010 | — | 33 patents Peptide-based cytokine vaccine compositions and lymphocyte selection technologies | — |
| 15 | Stimunity Virus like particles for non-responsive cancers | $4M | 77 mo ago | Seed | — | 2016 | — | 6 patents Immunotherapy peptide/biologic compositions for modulating immune responses | — |
| 16 | Honing Biosciences Developer of cell-based therapies to treat cancer and chronic diseases | $2M | 76 mo ago | Deadpooled | Abdelkader Bousabaa Founder | 2018 | — | 13 patents Engineering single-domain antibodies for HER2 cancer therapy and protein trafficking modulation. | — |
| 17 | IPSirius Developer of immunotherapies for cancer treatment | $2M | 49 mo ago | Funding Raised | Annelise Griscelli Co-Founder | 2019 | — | — | — |
| 18 | Biomunex Developer of antibody therapeutics for the treatment of cancer | $2M | 66 mo ago | Series A | Pierre-Emmanuel Gerard President and Founder | 2014 | WordPressMySQLPHP+16 | — | — |
Top 12 Immunotherapy companies in Paris
#1
Series A · Paris, Ile de France · founded 2020 · 28 employees$46.6Mraised▾
Provider of T cells-based therapeutics for oncology and autoimmune disease. The company offers computational-based IL-2 modified variants and translational-based therapeutic Treg targets to restore the immune response.
- Mar 2025Grant (prize money)$10.1M
- Oct 2021Series A$46.6M
#2
Public · Paris, Ile de France · founded 1999 · 236 employees$267.4Mraised▾
Developer of cancer immunotherapies based on gene-edited CAR T-cells. The company is developing products based on TALEN, its proprietary gene-editing technology, and PulseAgile, it's pioneering electroporation system to target cancer cells. It develops UCART products to treat multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL).
- May 2024Post IPO$140M
- Nov 2023Post IPO$105M
- Mar 2014Post IPO$22.4M
#3
Series B · Paris, Ile de France · founded 2013 · 35 employees$122.5Mraised▾
Inotrem is developing peptide immunotherapies for treating septic shock and acute myocardial infarction. The company is developing drugs that target the TREM-1 pathway. The company's lead candidate, Motrem, is a TREM-1 inhibitor and is a 12 amino-acid peptide, acting as a decoy receptor and interfering with the binding of TREM-1 and its ligand. It is being investigated for septic shock, and for acute myocardial infarction. The drug is in phase I trials.
- Nov 2023Grant (prize money)—
- Dec 2022Grant (prize money)—
- Feb 2020Conventional Debt$15.3M
- Feb 2020Series B$5.5M
#4
Public · Paris, Ile de France · founded 2014 · 26 employees$319.6Mraised▾
Developer of therapeutics for chronic inflammatory diseases. The lead drug candidate obefazimod is an oral, first-and-only small molecule with a novel mechanism of action that demonstrates enhanced expression of miR-124, which plays a critical role in the regulation of the inflammatory response. It is also develops products for Ulcerative Colitis, crohn's disease, and more.
- Feb 2023Post IPO$138.6M
- Sep 2022Post IPO$49.1M
- Jul 2021Post IPO$96.6M
- May 2020Grant (prize money)$21.7M
#5
Series A · Paris, Ile de France · founded 2015 · 2 employees$8.8Mraised▾
Developer of virus-derived vaccine technology to treat cancer. It offers Measovir platform that utilizes anti-cancer and immunogenic properties to produce effective new cancer treatments and vaccines.
- Nov 2023Series A$8.8M
#6
Series A · Paris, Ile de France · founded 2010 · 8 employees$6Mraised▾
Peptinov is specialized in the development of anti-cytokine immunotherapies (vaccines) for the treatment of chronic inflammatory diseases and cancer. It has developed three innovative vaccines against IL6, IL1, and IL23 cytokines, which have successfully been tested in mice and/or in monkeys. Its drug pipeline includes PPV-06 (anti-IL6 vaccine); PPV-01 (anti-IL1b vaccine); PPV-03 (anti-IL23 vaccine). It is developing these vaccines to treat chronic inflammatory diseases such as rheumatoid arthritis and systemic sclerosis. Also developing small molecule inhibitors of cytokines using the proprietary in silico drug design approach.
- Nov 2023Grant (prize money)$2.7M
- Nov 2023Series A$6M
#7
Series D · Paris, Ile de France · founded 2005 · 19 employees$62.1Mraised▾
Developer of vaccines to treat infectious diseases and cancer caused by HTLV-1 infection. By using the lentiviral immunotherapy platform the company has developed therapeutic vaccines for HIV, Hepatitis-B, Tuberculosis, and Adult T-cell Lymphoma-Leukaemia (ATL) induced by Human T-Lymphotropic Virus Type I (HTLV-1) infection.
- Feb 2021Series D$20M
- Apr 2017Series C$5.8M
- Jan 2015Grant (prize money)$2.1M
- Oct 2013Series C$19.9M
#8
Series A · Paris, Ile de France · founded 2018 · 56 employees$90.9Mraised▾
Developer of cell therapy platforms for tumors and blood cancers. The company has EnfiniT targeting and next-generation chimeric antigen receptors T cell therapy platform. It identifies antigens with tumor specificity that are present in cancer cells.
- Jun 2021Series A$90.9M
#9
Series B · Paris, Ile de France · founded 2020$26.1Mraised▾
Developer of therapies for the treatment of cancer and autoimmune diseases. It offers therapeutics that targets IL-1RAP, a unique antigen, which is upregulated in various cancers and autoimmune conditions. It offers CCTx-001 an IL-1RAP directed genetically modified autologous T-cell immunotherapy for the treatment of AML and ADV-101 is an ADC composed of humanized IgG1 monoclonal antibody for hematological and solid malignancies.
- Jan 2022Series B$26.1M
#10
Series A · Paris, Ile de France · founded 2019 · 9 employees$13.3Mraised▾
Ermium Therapeutic is developing therapies for auto-immune inflammatory diseases. The leading candidate of the company is CXCR4 which has antagonists action and can regulate the inflammation. The candidate helps in the production of type 1 interferons by plasmacytoid dendritic cells (pDC)for treating inflammatory diseases. The diseases targeted by the candidate are multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases, and others.
- Jun 2022Series A$6.3M
- Sep 2019Series A$7M
#11
Public · Paris, Ile de France · founded 2013 · 29 employees$31.4Mraised▾
Developing immunotherapeutics for treating ischemic stroke. The company engages in developing therapeutic monoclonal antibodies for the treatment of ischemic strokes. It offersin developing ACT-017, a humanized antibody for the treatment of cerebral stroke and the platelet glycoprotein VI.
- Nov 2019Series B$7.8M
- Oct 2018Series B$17.7M
- Jan 2018Grant (prize money)$2.6M
- Jan 2018Series B$2M
#12
Public · Paris, Ile de France · founded 1993$17.9Mraised▾
CDMO focused on manufacturing of vaccines
- Dec 2018Post IPO$2.6M
- Jun 2017Post IPO$4.1M
- Jun 2016Post IPO$9.1M
- Jul 2015Post IPO$8.3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology in Paris is moving
A read on the academic research around Immunology in Paris — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 366 papers.
- Assistance Publique – Hôpitaux de Paris237
- Université Paris Cité42
- Délégation Paris 533
- Université Paris-Saclay30
- CEA Paris-Saclay18
- Immunotherapy4→25
- Immune system3→22
- Immunogenic cell death1→8
- Programmed cell death1→7
- Cytotoxic T cell1→6
- Immunotherapy12→50
- Internal medicine5→30
- Oncology1→26
- Immune system6→30
- Nivolumab3→19
- Immunotherapy2→19
- Immune system2→12
- Disease1→8
- Internal medicine3→9
- Immune checkpoint1→5
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.